retatrutide phase 2 trial obesity nejm 2023 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis This data from Phase 3

Tirzepatide Tirzepatide is currently the only long-acting glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual receptor agonist

Follow the reconstitution guide carefully, store properly at 28C after reconstitution, and use our reconstitution calculator to ensure accurate dosing so you're not over-injecting

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF

Pregnant or breastfeeding women there is currently insufficient safety data to support use during pregnancy or lactation

With todays advanced, research-driven optionsSculptra, hyaluronic acid fillers, GLP-1tested skincare, and surgical rejuvenationwe can restore balance, volume, and radiance in a way that feels entirely you

Researchers believe Retatrutides three-pronged approach may explain its stronger effects on appetite suppression and calorie burning